CLINICAL TRIALS PROFILE FOR LOTEMAX
✉ Email this page to a colleague
All Clinical Trials for LOTEMAX
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00366691 ↗ | Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation | Completed | Medical University of South Carolina | Phase 4 | 2006-02-01 | The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery. |
NCT00407043 ↗ | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2006-11-01 | To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy. |
NCT00407043 ↗ | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis | Completed | Ophthalmic Consultants of Long Island | Phase 4 | 2006-11-01 | To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy. |
NCT00560638 ↗ | Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye | Completed | Bausch & Lomb Incorporated | Phase 2 | 2005-11-01 | This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTEMAX
Condition Name
Clinical Trial Locations for LOTEMAX
Trials by Country
Clinical Trial Progress for LOTEMAX
Clinical Trial Phase
Clinical Trial Sponsors for LOTEMAX
Sponsor Name